These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33027748)

  • 1. Renal protection with glucagon-like peptide-1 receptor agonists.
    Vitale M; Haxhi J; Cirrito T; Pugliese G
    Curr Opin Pharmacol; 2020 Oct; 54():91-101. PubMed ID: 33027748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
    Thomas MC
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.
    Trevella P; Ekinci EI; MacIsaac RJ
    Nephrology (Carlton); 2024 Aug; 29(8):457-469. PubMed ID: 39030739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 Receptor Agonists and Kidney Protection.
    Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Prattichizzo F; de Candia P; Ceriello A
    Metabolism; 2021 Jul; 120():154799. PubMed ID: 34029597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB; van Raalte DH
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
    DeFronzo RA
    Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.
    Kuang Z; Hou N; Kan C; Han F; Qiu H; Sun X
    Int Urol Nephrol; 2023 Mar; 55(3):617-629. PubMed ID: 36036316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
    Lee B; Holstein-Rathlou NH; Sosnovtseva O; Sørensen CM
    Am J Physiol Cell Physiol; 2023 Jul; 325(1):C243-C256. PubMed ID: 37273240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.